NASDAQ:JAGX - Jaguar Health Stock Price, Price Target & More

$0.1625 0.00 (0.00 %)
(As of 04/25/2018 02:35 AM ET)
Previous Close$0.1625
Today's Range$0.1620 - $0.17
52-Week Range$0.10 - $0.99
Volume1.43 million shs
Average Volume9.44 million shs
Market Capitalization$27.57 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.52

About Jaguar Health (NASDAQ:JAGX)

Jaguar Health logoJaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing novel, sustainably derived gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Canalevia is the company's lead animal prescription drug product candidate intended for treatment of various forms of diarrhea in dogs; and Equilevia is Jaguar's non-prescription product for total gut health in equine athletes. Canalevia and Equilevia contain ingredients isolated and purified from the Croton lechleri tree, which is sustainably harvested. In addition, the Company's products include Neonorm Calf and Neonorm Foal. Mytesi, Canalevia, Equilevia, and Neonorm are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar Health, Inc. is based in San Francisco, California.

Receive JAGX News and Ratings via Email

Sign-up to receive the latest news and ratings for JAGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:JAGX
CUSIPN/A
Phone415-371-8300

Debt

Debt-to-Equity Ratio0.64%
Current Ratio0.25%
Quick Ratio0.11%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.36 million
Price / Sales6.27
Cash FlowN/A
Price / CashN/A
Book Value$0.16 per share
Price / Book1.02

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-21,960,000.00
Net Margins-502.65%
Return on Equity-188.56%
Return on Assets-61.60%

Miscellaneous

Employees36
Outstanding Shares168,320,000

How to Become a New Pot Stock Millionaire

Jaguar Health (NASDAQ:JAGX) Frequently Asked Questions

What is Jaguar Health's stock symbol?

Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."

How were Jaguar Health's earnings last quarter?

Jaguar Health (NASDAQ:JAGX) posted its quarterly earnings data on Monday, November, 14th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.10. The biotechnology company had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.10 million. Jaguar Health had a negative net margin of 502.65% and a negative return on equity of 188.56%. View Jaguar Health's Earnings History.

What price target have analysts set for JAGX?

2 brokers have issued 12-month price targets for Jaguar Health's stock. Their predictions range from $2.00 to $2.00. On average, they anticipate Jaguar Health's share price to reach $2.00 in the next twelve months. View Analyst Ratings for Jaguar Health.

Are investors shorting Jaguar Health?

Jaguar Health saw a increase in short interest in the month of March. As of March 29th, there was short interest totalling 6,865,074 shares, an increase of 36.5% from the March 15th total of 5,027,707 shares. Based on an average daily volume of 6,371,217 shares, the short-interest ratio is currently 1.1 days. Currently, 8.9% of the company's stock are short sold.

Who are some of Jaguar Health's key competitors?

Who are Jaguar Health's key executives?

Jaguar Health's management team includes the folowing people:
  • Ms. Lisa A. Conte, Founder, CEO & Exec. Director (Age 59)
  • Ms. Karen S. Wright, Chief Financial Officer (Age 62)
  • Dr. Pravin R. Chaturvedi, Chairman of Scientific Advisory Board & Pres (Age 55)
  • Mr. Peter Hodge, Director of Investor Relations & Market Research
  • Mr. Pete Riojas, National Sales Director

When did Jaguar Health IPO?

(JAGX) raised $22 million in an initial public offering on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp acted as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

Has Jaguar Health been receiving favorable news coverage?

News headlines about JAGX stock have trended somewhat positive this week, Accern reports. Accern identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Jaguar Health earned a daily sentiment score of 0.20 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 44.92 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Jaguar Health's major shareholders?

Jaguar Health's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Sagard Capital Partners, L.P. (22.60%) and Sagard Capital Partners, L.P. (22.60%). View Institutional Ownership Trends for Jaguar Health.

How do I buy shares of Jaguar Health?

Shares of JAGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Jaguar Health's stock price today?

One share of JAGX stock can currently be purchased for approximately $0.1625.

How big of a company is Jaguar Health?

Jaguar Health has a market capitalization of $27.57 million and generates $4.36 million in revenue each year. Jaguar Health employs 36 workers across the globe.

How can I contact Jaguar Health?

Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The biotechnology company can be reached via phone at 415-371-8300.


MarketBeat Community Rating for Jaguar Health (JAGX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  117 (Vote Outperform)
Underperform Votes:  109 (Vote Underperform)
Total Votes:  226
MarketBeat's community ratings are surveys of what our community members think about Jaguar Health and other stocks. Vote "Outperform" if you believe JAGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAGX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Jaguar Health (NASDAQ:JAGX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Jaguar Health in the last 12 months. Their average twelve-month price target is $2.00, suggesting that the stock has a possible upside of 1,130.77%. The high price target for JAGX is $2.00 and the low price target for JAGX is $2.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.00$2.00$2.00$2.00
Price Target Upside: 1,130.77% upside281.32% upside281.32% upside281.32% upside

Jaguar Health (NASDAQ:JAGX) Consensus Price Target History

Price Target History for Jaguar Health (NASDAQ:JAGX)

Jaguar Health (NASDAQ:JAGX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/11/2017HC WainwrightSet Price TargetBuy$2.00HighView Rating Details
7/11/2017Rodman & RenshawInitiated CoverageBuy -> Buy$2.00HighView Rating Details
6/13/2016AegisReiterated RatingBuy$10.00N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Jaguar Health (NASDAQ:JAGX) Earnings History and Estimates Chart

Earnings by Quarter for Jaguar Health (NASDAQ:JAGX)

Jaguar Health (NASDAQ JAGX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/20/2017Q3 2017$0.13$1.61 million$1.10 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.22)($0.12)$1.34 million$0.90 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.28)$0.82 millionViewN/AView Earnings Details
2/15/2017Q4 2016($0.28)$0.03 millionViewN/AView Earnings Details
11/14/20169/30/2016($0.40)($0.30)$0.10 million$0.05 millionViewN/AView Earnings Details
8/15/2016Q2 2016($0.42)($0.35)$0.10 million$0.02 millionViewN/AView Earnings Details
5/10/2016Q1 2016($0.49)($0.43)$0.10 million$0.04 millionViewN/AView Earnings Details
3/29/2016Q4 2015($0.42)$0.06 millionViewN/AView Earnings Details
11/13/2015Q3 2015($0.49)($0.36)$0.10 million$0.08 millionViewN/AView Earnings Details
8/13/2015Q2 2015($0.97)$0.06 millionViewN/AView Earnings Details
6/26/2015Q1 2015($1.32)$0.06 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Jaguar Health (NASDAQ:JAGX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Jaguar Health (NASDAQ JAGX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.30%
Institutional Ownership Percentage: 7.00%
Insider Trading History for Jaguar Health (NASDAQ:JAGX)
Institutional Ownership by Quarter for Jaguar Health (NASDAQ:JAGX)

Jaguar Health (NASDAQ JAGX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/8/2016James J BochnowskiDirectorBuy160,000$2.50$400,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Jaguar Health (NASDAQ JAGX) News Headlines

Source:
DateHeadline
Experts Highlight that Immune System Activation in Aging Patients Living with HIV/AIDS Triggers Effects Such as "Leaky Gut", Which Can Lead to DiarrheaExperts Highlight that Immune System Activation in Aging Patients Living with HIV/AIDS Triggers Effects Such as "Leaky Gut", Which Can Lead to Diarrhea
finance.yahoo.com - April 19 at 5:33 PM
Form PRE 14A Jaguar Health, Inc. For: May 18Form PRE 14A Jaguar Health, Inc. For: May 18
www.streetinsider.com - April 17 at 8:40 AM
Jaguar Health Inc (JAGX) Sees Large Increase in Short InterestJaguar Health Inc (JAGX) Sees Large Increase in Short Interest
www.americanbankingnews.com - April 13 at 2:10 AM
Jaguar Subsidiary Napo Pharmaceuticals Signs Agreement with the ADAP Crisis Task Force for MytesiJaguar Subsidiary Napo Pharmaceuticals Signs Agreement with the ADAP Crisis Task Force for Mytesi
finance.yahoo.com - April 10 at 5:24 PM
Recent Publications Indicate that Diarrhea is a Significant and Serious Issue in HIVRecent Publications Indicate that Diarrhea is a Significant and Serious Issue in HIV
finance.yahoo.com - April 9 at 5:15 PM
Jaguar Health Appoints Jonathan B. Siegel to Board of DirectorsJaguar Health Appoints Jonathan B. Siegel to Board of Directors
finance.yahoo.com - April 2 at 5:21 PM
Jaguar Health Announces Up to $16.2 Million in Equity Financings in Separate Private Placement Investments, Including Investment by Sagard Capital Partners, L.P., to Continue Commercialization of FDA-Approved MytesiJaguar Health Announces Up to $16.2 Million in Equity Financings in Separate Private Placement Investments, Including Investment by Sagard Capital Partners, L.P., to Continue Commercialization of FDA-Approved Mytesi
finance.yahoo.com - March 26 at 8:29 AM
ValuEngine Upgrades Jaguar Health (JAGX) to SellValuEngine Upgrades Jaguar Health (JAGX) to Sell
www.americanbankingnews.com - March 25 at 4:48 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an ... - Business Wire (press release)SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an ... - Business Wire (press release)
www.businesswire.com - March 14 at 8:44 AM
Traders News Source: Jaguar Health, Pipeline Review , Analyst Ratings, MilestonesTraders News Source: Jaguar Health, Pipeline Review , Analyst Ratings, Milestones
www.finanznachrichten.de - March 13 at 7:12 PM
Jaguar Health, Pipeline Review, Analyst Ratings, MilestonesJaguar Health, Pipeline Review, Analyst Ratings, Milestones
finance.yahoo.com - March 13 at 7:12 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Jaguar Health, Inc.SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Jaguar Health, Inc.
finance.yahoo.com - March 13 at 7:12 PM
Why Jaguar Health Inc’s (NASDAQ:JAGX) CEO Pay Matters To YouWhy Jaguar Health Inc’s (NASDAQ:JAGX) CEO Pay Matters To You
finance.yahoo.com - March 13 at 7:12 PM
Jaguar Health, Inc. (JAGX)Jaguar Health, Inc. (JAGX)
finance.yahoo.com - March 10 at 8:29 AM
Today’s Research Reports on Stocks to Watch: Atossa Genetics and Jaguar HealthToday’s Research Reports on Stocks to Watch: Atossa Genetics and Jaguar Health
finance.yahoo.com - March 9 at 8:27 AM
Jaguar Health Stock Explodes on FDA NewsJaguar Health Stock Explodes on FDA News
www.baystreet.ca - March 8 at 6:30 PM
FDA Indicates that Jaguars Reasonable Expectation of Effectiveness Technical Section is Complete for Use of Canalevia for Treatment of Chemotherapy-Induced Diarrhea in DogsFDA Indicates that Jaguar's Reasonable Expectation of Effectiveness Technical Section is Complete for Use of Canalevia for Treatment of Chemotherapy-Induced Diarrhea in Dogs
finance.yahoo.com - March 8 at 6:30 PM
Jaguar Health Subsidiary, Napo Pharmaceuticals, Signs Agreement with Pharmacy Services Provider "Transition Patient Services" to Establish Nationwide Pilot "Mytesi Direct" ProgramJaguar Health Subsidiary, Napo Pharmaceuticals, Signs Agreement with Pharmacy Services Provider "Transition Patient Services" to Establish Nationwide Pilot "Mytesi Direct" Program
finance.yahoo.com - March 2 at 6:02 PM
How Financially Strong Is Jaguar Health Inc (NASDAQ:JAGX)?How Financially Strong Is Jaguar Health Inc (NASDAQ:JAGX)?
finance.yahoo.com - March 1 at 5:46 PM
Jaguar Health Inc (JAGX) Sees Significant Growth in Short InterestJaguar Health Inc (JAGX) Sees Significant Growth in Short Interest
www.americanbankingnews.com - February 9 at 5:00 PM
Jaguar Health (JAGX) & Shire Viropharma (VPHM) Head-To-Head ContrastJaguar Health (JAGX) & Shire Viropharma (VPHM) Head-To-Head Contrast
www.americanbankingnews.com - January 26 at 5:06 AM
at 4:15 pm Eastern Time to Provide Updates Regarding Jaguar and Napo Pharmaceuticals Commercial, Educational ... - Business Wire (press release)at 4:15 pm Eastern Time to Provide Updates Regarding Jaguar and Napo Pharmaceuticals Commercial, Educational ... - Business Wire (press release)
www.businesswire.com - January 19 at 8:12 AM
Form 8-K Jaguar Health, Inc. For: Jan 18 - StreetInsider.comForm 8-K Jaguar Health, Inc. For: Jan 18 - StreetInsider.com
www.streetinsider.com - January 19 at 8:12 AM
Napo Pharmaceuticals Comments on the Passing of HIV/AIDS Activist and Research Pioneer Dr. Mathilde KrimNapo Pharmaceuticals Comments on the Passing of HIV/AIDS Activist and Research Pioneer Dr. Mathilde Krim
finance.yahoo.com - January 18 at 7:09 PM
Jaguar Health to Host Conference Call Monday, January 22nd at 4:15 p.m. Eastern Time to Provide Updates Regarding Jaguar and Napo Pharmaceuticals Commercial, Educational & Product Development Activities and 2017 ResultsJaguar Health to Host Conference Call Monday, January 22nd at 4:15 p.m. Eastern Time to Provide Updates Regarding Jaguar and Napo Pharmaceuticals Commercial, Educational & Product Development Activities and 2017 Results
finance.yahoo.com - January 18 at 7:09 PM
Critical Contrast: Cleveland BioLabs (CBLI) vs. Jaguar Health (JAGX)Critical Contrast: Cleveland BioLabs (CBLI) vs. Jaguar Health (JAGX)
www.americanbankingnews.com - January 10 at 3:08 AM
Jaguar Health Inc (NASDAQ:JAGX): Has Recent Earnings Growth Beaten Long-Term Trend?Jaguar Health Inc (NASDAQ:JAGX): Has Recent Earnings Growth Beaten Long-Term Trend?
finance.yahoo.com - January 6 at 3:55 PM
Jaguar Health, Inc. :JAGX-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018Jaguar Health, Inc. :JAGX-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018
finance.yahoo.com - January 1 at 10:48 AM
WallStreet Research(TM) Announces Release of Corporate Profile Coverage on Jaguar Health, Inc. (NASDAQ: JAGX)WallStreet Research(TM) Announces Release of Corporate Profile Coverage on Jaguar Health, Inc. (NASDAQ: JAGX)
finance.yahoo.com - December 26 at 12:03 PM
Jaguar Animal Health (JAGX) and Dubai-based Seed Mena Enter Collaboration Agreement for Equilevia - StreetInsider.comJaguar Animal Health (JAGX) and Dubai-based Seed Mena Enter Collaboration Agreement for Equilevia - StreetInsider.com
www.streetinsider.com - December 14 at 11:17 AM
Jaguar Health and Dubai-based Seed Mena Enter Collaboration Agreement for Equilevia, Jaguar’s Personalized, Premium Product for Total Gut Health and Wellness in HorsesJaguar Health and Dubai-based Seed Mena Enter Collaboration Agreement for Equilevia, Jaguar’s Personalized, Premium Product for Total Gut Health and Wellness in Horses
finance.yahoo.com - December 14 at 11:17 AM
New Survey Finds People Living With HIV With Diarrhea Often Suffer in SilenceNew Survey Finds People Living With HIV With Diarrhea Often Suffer in Silence
finance.yahoo.com - December 12 at 11:44 AM
Zacks: Jaguar Health Inc (JAGX) Given $6.00 Consensus Price Target by AnalystsZacks: Jaguar Health Inc (JAGX) Given $6.00 Consensus Price Target by Analysts
www.americanbankingnews.com - December 10 at 9:37 PM
Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Friday, December 15, 2017 - Business Wire (press release)Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Friday, December 15, 2017 - Business Wire (press release)
www.businesswire.com - December 1 at 6:18 PM
Keep Your Pants On Campaign From Napo Pharmaceuticals Chosen as Best HIV-Related Awareness Campaign of 2017 by HealthlineKeep Your Pants On Campaign From Napo Pharmaceuticals Chosen as Best HIV-Related Awareness Campaign of 2017 by Healthline
finance.yahoo.com - December 1 at 6:18 PM
Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Friday, December 15, 2017Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Friday, December 15, 2017
finance.yahoo.com - December 1 at 6:18 PM
What You Must Know About Jaguar Health Inc’s (JAGX) Financial StrengthWhat You Must Know About Jaguar Health Inc’s (JAGX) Financial Strength
finance.yahoo.com - November 30 at 3:53 PM
Jaguar Animal Health (JAGX) Enters Share Purchase Agreement for 2M Shares and Common Stock Purchase ... - StreetInsider.comJaguar Animal Health (JAGX) Enters Share Purchase Agreement for 2M Shares and Common Stock Purchase ... - StreetInsider.com
www.streetinsider.com - November 29 at 11:10 AM
Jaguar Health Enters Share Purchase Agreement for 2 Million Shares and Common Stock Purchase Agreement Relating to a 10 Million Share Equity Line Offering With L2 Capital, LLCJaguar Health Enters Share Purchase Agreement for 2 Million Shares and Common Stock Purchase Agreement Relating to a 10 Million Share Equity Line Offering With L2 Capital, LLC
finance.yahoo.com - November 27 at 5:18 PM
Jaguar Health Files First Quarterly Earnings Report Since July 2017 Merger with Napo Pharmaceuticals - Business Wire (press release)Jaguar Health Files First Quarterly Earnings Report Since July 2017 Merger with Napo Pharmaceuticals - Business Wire (press release)
www.businesswire.com - November 22 at 1:19 AM
Jaguar Health Files First Quarterly Earnings Report Since July 2017 Merger with Napo PharmaceuticalsJaguar Health Files First Quarterly Earnings Report Since July 2017 Merger with Napo Pharmaceuticals
finance.yahoo.com - November 21 at 1:58 AM
Jaguar Health Presenting Neonorm Calf at Western Organic Dairy ... - Business Wire (press release)Jaguar Health Presenting Neonorm Calf at Western Organic Dairy ... - Business Wire (press release)
www.businesswire.com - November 17 at 8:19 AM
Jaguar Healths (JAGX) CEO Lisa Conte on First Post-Merger Earnings Call - Earnings Call Transcript - Seeking AlphaJaguar Health's (JAGX) CEO Lisa Conte on First Post-Merger Earnings Call - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 17 at 8:19 AM
Dr. Roscoe M. Moore Jr., DVM, MPH, Ph.D., DSc Joins Napo Pharmaceuticals Scientific Advisory Board for HIV for Mytesi, Napo’s FDA-Approved Human Prescription DrugDr. Roscoe M. Moore Jr., DVM, MPH, Ph.D., DSc Joins Napo Pharmaceuticals Scientific Advisory Board for HIV for Mytesi, Napo’s FDA-Approved Human Prescription Drug
finance.yahoo.com - November 17 at 8:19 AM
Jaguar Health Presenting Neonorm Calf at Western Organic Dairy Producers Alliance ConferenceJaguar Health Presenting Neonorm Calf at Western Organic Dairy Producers Alliance Conference
finance.yahoo.com - November 17 at 8:19 AM
Is Jaguar Health Inc (JAGX) A Healthcare Industry Laggard Or Leader?Is Jaguar Health Inc (JAGX) A Healthcare Industry Laggard Or Leader?
finance.yahoo.com - November 15 at 3:28 AM
Today’s Jaguar Health Conference Call Moved to 5:45 p.m. Eastern TimeToday’s Jaguar Health Conference Call Moved to 5:45 p.m. Eastern Time
finance.yahoo.com - November 15 at 3:28 AM
Year-to-Date Gross Sales for Mytesi, the FDA-Approved Human Prescription Drug Product of Jaguar Health’s Wholly-Owned Subsidiary, Napo Pharmaceuticals, Total $2.8 MillionYear-to-Date Gross Sales for Mytesi, the FDA-Approved Human Prescription Drug Product of Jaguar Health’s Wholly-Owned Subsidiary, Napo Pharmaceuticals, Total $2.8 Million
finance.yahoo.com - November 15 at 3:28 AM
Jaguar Health to Host Earnings Conference Call Tuesday, November 14th at 4:30 p.m. Eastern TimeJaguar Health to Host Earnings Conference Call Tuesday, November 14th at 4:30 p.m. Eastern Time
finance.yahoo.com - November 11 at 2:14 PM
Analyzing Jaguar Animal Health (JAGX) and Its PeersAnalyzing Jaguar Animal Health (JAGX) and Its Peers
www.americanbankingnews.com - November 11 at 1:28 AM

SEC Filings

Jaguar Health (NASDAQ:JAGX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Jaguar Health (NASDAQ:JAGX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Jaguar Health (NASDAQ JAGX) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.